Commerzbank Aktiengesellschaft Bluebird Bio, Inc. Transaction History

Commerzbank Aktiengesellschaft

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 06, 2019	SELL	$59.1 - $93.26 $470,317 - $742,163	-7,958 Closed	0 $0
Q3 2018 Oct 04, 2024	BUY	$88.86 - $117.49 $707,147 - $934,985	7,958 New	7,958 $1.16 Million
Q2 2018 Oct 04, 2024	BUY	$99.64 - $127.59 $792,935 - $1.02 Million	7,958 New	7,958 $1.25 Million
Q2 2018 Aug 10, 2018	SELL	$99.64 - $127.59 $14,647 - $18,755	-147 Reduced 1.81%	7,958 $1.25 Million
Q1 2018 Oct 04, 2024	SELL	$105.8 - $150.94 $13,542 - $19,320	-128 Reduced 1.55%	8,105 $1.38 Million
Q1 2018 May 01, 2018	SELL	$105.8 - $150.94 $13,542 - $19,320	-128 Reduced 1.55%	8,105 $1.38 Million
Q4 2017 Oct 04, 2024	BUY	$81.25 - $130.7 $668,931 - $1.08 Million	8,233 New	8,233 $1.47 Million
Q4 2017 Jan 26, 2018	SELL	$81.25 - $130.7 $112,368 - $180,758	-1,383 Reduced 14.38%	8,233 $1.47 Million
Q3 2017 Nov 13, 2017	BUY	$57.74 - $91.42 $233,904 - $370,342	4,051 Added 72.79%	9,616 $1.32 Million
Q2 2017 Aug 09, 2017	BUY	N/A	5,565	5,565 $585,000

112

61.5M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $485M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Commerzbank Aktiengesellschaft , based on Form 13F filings with the SEC.

Stay updated on Commerzbank Aktiengesellschaft with notifications on news.